

Press Information

AOI Medical, Inc. Treats Fifty-Four (54) Patients in Ascendx™ VCF Reduction System Clinical Trial

London, UK, 30 July 2009 - [AOI Medical, Inc.](http://www.aomedical.com) (the "Company" or "AOI") (AIM: AOI), a medical device company focusing on innovative orthopaedic medical devices for the spine and trauma markets, has successfully completed surgical procedures on fifty-four (54) patients in a clinical trial with Ascendx™ Vertebral Compression Fracture ("VCF") Reduction System ("Ascendx™") at eight sites across the United States. AOI has treated ten (10) patients since the last Company announcement on 24 June 2009. The board is pleased with the progress of the clinical trial and results to date; evaluation of clinical outcomes is ongoing.

William J. Christy, CEO of AOI, said: "This is an exciting time in AOI's history as we near the completion of our sixty (60) patient Ascendx™ clinical trial and we are very pleased with the progress we have made to date. The Ascendx™ system is designed to provide notable improvements in the way physicians traditionally treat VCFs. While all currently existing VCF procedures offer immediate pain relief to the patient, the Ascendx™ technology is specifically designed to provide a mechanical, repeatable cutting of cancellous bone and to deliver an even distribution of the bone cement. Over time, these features may potentially provide benefits with respect to clinical outcomes, subject to ongoing clinical evaluation."

The single arm trial of Ascendx™ will ultimately involve sixty (60) subjects, with the primary end point being acute procedural success defined as successful device deployment, cement delivery, and device withdrawal. The data from the trial will be used as clinical support for the Company's 510(k) submission to the FDA in relation to Ascendx™. The clinical trial is expected to complete its final patient enrollment and make its 510(k) submission to the FDA later this year. The Company believes that it remains on target for a market launch of Ascendx™ in the United States in Q1 2010.

For more news and information on AOI Medical, Inc., please visit www.IRGnews.com/coi/AOI where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

About Ascendx™

Ascendx™ is an investigational device which comprises a set of tools specifically designed for use in the treatment of painful pathological fractures of the vertebral body that may result from osteoporosis, benign lesions and/or malignant lesions such as metastatic cancers and myeloma. Ascendx™ will comprise two main instruments: a cutting device that creates a cavity in cancellous bone, and a reduction device that is used to restore the height of the fractured vertebra and which can deliver and contain the bio-material (bonding agent) in the cavity. The set of tools is designed to offer a potential enhancement over current techniques. Ascendx™ is an investigational device limited to investigational use in the ongoing IDE study in the United States.

Ascendx™ presents an attractive market opportunity. The size of the market is estimated to be in the region of USD700 million annually, rising to over USD900 million by 2012 (source: CRT Capital, LLC 2008).

Enquiries:

AOI Medical, Inc.
William J. Christy, CEO

Tel: +1 407 770 1800

Numis Securities Limited
Nominated Adviser: Michael Meade / Brent Nabbs

Tel: +44 (0) 20 7260 1000

Corporate Broking: David Poutney

The Investor Relations Group

Erika Moran/Tom Caden

Public Relations: Susan Morgenbesser

Tel: +1 212 825 3210

Background to AOI Medical, Inc.

AOI is a medical device company focusing on the development and commercialisation of innovative orthopaedic medical devices for the spine and trauma markets. It is progressing the development of three separate technology platforms: Ascendx™ VCF Reduction System, BAMF Trauma and Cervical Plate. Further information can be found at www.aoimedical.net